Compare Stocks: ANNX, TLX, LEGN, and RCUS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANNX Annexon	$5.41 -3.4%	$5.36	$2.03 ▼ $7.18	$917.52M	1.18	3.30 million shs	2.05 million shs
LEGN Legend Biotech	$20.75 +7.6%	$27.07	$16.24 ▼ $38.35	$3.58B	0.37	2.80 million shs	2.61 million shs
RCUS Arcus Biosciences	$28.67 +1.2%	$27.40	$8.88 ▼ $31.74	$3.61B	0.8	1.11 million shs	1.06 million shs
TLX Telix Pharmaceuticals	$11.52 +8.3%	$10.44	$6.28 ▼ $12.60	$3.62B	-0.24	109,904 shs	212,039 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANNX Annexon	-3.39%	+6.29%	-9.23%	-4.92%	+130.21%
LEGN Legend Biotech	+7.62%	+11.86%	-25.55%	-26.21%	-44.90%
RCUS Arcus Biosciences	+1.55%	+1.74%	-6.01%	+12.98%	+202.25%
TLX Telix Pharmaceuticals	+8.27%	+16.48%	-0.26%	+7.87%	-3.76%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANNX Annexon	$5.41 -3.4%	$5.36	$2.03 ▼ $7.18	$917.52M	1.18	3.30 million shs	2.05 million shs
LEGN Legend Biotech	$20.75 +7.6%	$27.07	$16.24 ▼ $38.35	$3.58B	0.37	2.80 million shs	2.61 million shs
RCUS Arcus Biosciences	$28.67 +1.2%	$27.40	$8.88 ▼ $31.74	$3.61B	0.8	1.11 million shs	1.06 million shs
TLX Telix Pharmaceuticals	$11.52 +8.3%	$10.44	$6.28 ▼ $12.60	$3.62B	-0.24	109,904 shs	212,039 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANNX Annexon	-3.39%	+6.29%	-9.23%	-4.92%	+130.21%
LEGN Legend Biotech	+7.62%	+11.86%	-25.55%	-26.21%	-44.90%
RCUS Arcus Biosciences	+1.55%	+1.74%	-6.01%	+12.98%	+202.25%
TLX Telix Pharmaceuticals	+8.27%	+16.48%	-0.26%	+7.87%	-3.76%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANNX Annexon	2.20	Hold	$15.33	183.43% Upside
LEGN Legend Biotech	2.53	Moderate Buy	$55.29	166.44% Upside
RCUS Arcus Biosciences	2.58	Moderate Buy	$37.70	31.51% Upside
TLX Telix Pharmaceuticals	2.63	Moderate Buy	$20.40	77.08% Upside

Current Analyst Ratings Breakdown

Latest ANNX, TLX, LEGN, and RCUS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2026	RCUS Arcus Biosciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$42.00
8/6/2026	RCUS Arcus Biosciences	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$41.00 ➝ $43.00
8/6/2026	RCUS Arcus Biosciences	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$23.00 ➝ $26.00
7/30/2026	LEGN Legend Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/28/2026	LEGN Legend Biotech	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/28/2026	LEGN Legend Biotech	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$65.00
7/27/2026	LEGN Legend Biotech	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$49.00 ➝ $28.00
7/27/2026	LEGN Legend Biotech	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$58.00
7/27/2026	LEGN Legend Biotech	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$63.00 ➝ $59.00
7/24/2026	LEGN Legend Biotech	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$49.00 ➝ $28.00
7/21/2026	ANNX Annexon	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Market Underperform

(Data available from 8/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANNX Annexon	N/A	N/A	N/A	N/A	$1.42 per share	N/A
LEGN Legend Biotech	$1.03B	3.75	N/A	N/A	$5.43 per share	3.82
RCUS Arcus Biosciences	$247M	14.78	N/A	N/A	$3.64 per share	7.88
TLX Telix Pharmaceuticals	$803.79M	4.87	$0.05 per share	252.35	$1.23 per share	9.37

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANNX Annexon	-$206.69M	-$1.22	N/A	N/A	N/A	N/A	-101.19%	-75.99%	8/13/2026 (Estimated)
LEGN Legend Biotech	-$296.80M	-$0.68	N/A	13.30	N/A	-21.98%	-24.92%	-14.87%	8/11/2026 (Estimated)
RCUS Arcus Biosciences	-$353M	-$3.18	N/A	N/A	N/A	-393.16%	-89.54%	-45.61%	10/27/2026 (Estimated)
TLX Telix Pharmaceuticals	-$7.12M	N/A	N/A	104.73	N/A	N/A	N/A	N/A	8/20/2026 (Estimated)

Latest ANNX, TLX, LEGN, and RCUS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/20/2026	H1 2026	TLX Telix Pharmaceuticals	$0.0434	N/A	N/A	N/A	$479.63 million	N/A
8/13/2026	Q2 2026	ANNX Annexon	-$0.23	N/A	N/A	N/A	$6.50 million	N/A
8/11/2026	Q2 2026	LEGN Legend Biotech	$0.0563	N/A	N/A	N/A	$355.96 million	N/A
8/5/2026	Q2 2026	RCUS Arcus Biosciences	-$0.8912	-$0.72	+$0.1712	-$0.72	$21.98 million	$41.00 million
5/13/2026	Q1 2026	LEGN Legend Biotech	-$0.02	-$0.03	-$0.01	-$0.30	$306.51 million	$305.10 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANNX Annexon	N/A	N/A	N/A	N/A	N/A
LEGN Legend Biotech	N/A	N/A	N/A	N/A	N/A
RCUS Arcus Biosciences	N/A	N/A	N/A	N/A	N/A
TLX Telix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANNX Annexon	N/A	6.35	6.35
LEGN Legend Biotech	N/A	2.13	2.05
RCUS Arcus Biosciences	0.22	3.82	4.04
TLX Telix Pharmaceuticals	1.08	1.43	1.27

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANNX Annexon	N/A
LEGN Legend Biotech	70.89%
RCUS Arcus Biosciences	92.89%
TLX Telix Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
ANNX Annexon	10.31%
LEGN Legend Biotech	0.02%
RCUS Arcus Biosciences	7.60%
TLX Telix Pharmaceuticals	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANNX Annexon	60	163.84 million	146.95 million	Optionable
LEGN Legend Biotech	2,965	185.74 million	185.70 million	Optionable
RCUS Arcus Biosciences	500	127.33 million	116.21 million	Optionable
TLX Telix Pharmaceuticals	1,184	339.78 million	N/A	N/A

ANNX, TLX, LEGN, and RCUS Headlines

Recent News About These Companies

Telix to host R&D Day in New York on 22 September

August 6 at 8:35 AM | msn.com

Telix to Host R&D Day in New York City on September 22, 2026

August 5 at 7:00 AM | globenewswire.com

Health check: Telix jumps first hurdle with its advanced prostate cancer therapy trial

August 3, 2026 | msn.com

CSL vs Telix shares: Which is the better buy?

August 3, 2026 | msn.com

Telix Pharmaceuticals: The Radiopharma Operating System Is The Real Moat

July 31, 2026 | seekingalpha.com

HC Wainwright Has Pessimistic Outlook of TLX FY2026 Earnings

July 31, 2026 | americanbankingnews.com

Telix H1 2026 Results: Investor Webcast Notification

July 30, 2026 | finance.yahoo.com

Short Interest in Telix Pharmaceuticals Limited (NASDAQ:TLX) Increases By 82.7%

July 30, 2026 | marketbeat.com

Equities Analysts Set Expectations for TLX FY2026 Earnings

July 29, 2026 | marketbeat.com

Does Telix Pharmaceuticals Limited (TLX) Have the Potential to Rally 86.17% as Wall Street Analysts Expect?

July 22, 2026 | zacks.com

Tuesday's HotCopper trends: Telix Pharma, Larvotto, Evion Group, and other daily topics

July 21, 2026 | msn.com

Are Telix shares a buy, hold or sell following results?

July 21, 2026 | fool.com.au

Telix doses first patient in phase 3 renal cancer trial

July 21, 2026 | msn.com

Up 79% since February, why are Telix shares jumping higher again on Tuesday?

July 21, 2026 | fool.com.au

Telix Pharmaceuticals: Q2 2026 revenue jumps 21%

July 21, 2026 | fool.com.au

TLX591-Tx ProstACT SELECT Study Published in Cancers Journal

July 21, 2026 | globenewswire.com

Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress

July 20, 2026 | markets.businessinsider.com

Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress

July 20, 2026 | globenewswire.com

Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer

July 20, 2026 | globenewswire.com

Telix Pharmaceuticals (NASDAQ:TLX) Downgraded by Royal Bank Of Canada to Sector Perform

July 17, 2026 | marketbeat.com

Telix completes Japan phase 3 enrollment for Illuccix

July 17, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANNX, TLX, LEGN, and RCUS Company Descriptions

Annexon NASDAQ:ANNX

$5.41 -0.19 (-3.39%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$5.44 +0.02 (+0.46%)

As of 08/7/2026 07:34 PM Eastern

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Legend Biotech NASDAQ:LEGN

$20.75 +1.47 (+7.62%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$20.72 -0.03 (-0.15%)

As of 08/7/2026 07:56 PM Eastern

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

Arcus Biosciences NYSE:RCUS

$28.67 +0.34 (+1.19%)

Closing price 08/7/2026 03:59 PM Eastern

Extended Trading

$29.24 +0.57 (+2.00%)

As of 08/7/2026 07:34 PM Eastern

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

Telix Pharmaceuticals NASDAQ:TLX

$11.52 +0.88 (+8.27%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$11.50 -0.01 (-0.13%)

As of 08/7/2026 07:49 PM Eastern

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ANNX, TLX, LEGN, and RCUS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ANNX, TLX, LEGN, and RCUS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ANNX, TLX, LEGN, and RCUS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANNX, TLX, LEGN, and RCUS Company Descriptions

Annexon NASDAQ:ANNX

Legend Biotech NASDAQ:LEGN

Arcus Biosciences NYSE:RCUS

Telix Pharmaceuticals NASDAQ:TLX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ANNX, TLX, LEGN, and RCUS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ANNX, TLX, LEGN, and RCUS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ANNX, TLX, LEGN, and RCUS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANNX, TLX, LEGN, and RCUS Company Descriptions

Annexon NASDAQ:ANNX

Legend Biotech NASDAQ:LEGN

Arcus Biosciences NYSE:RCUS

Telix Pharmaceuticals NASDAQ:TLX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools